Merck Sharp & Dohme


Zuellig Pharma


A. Menarini
Concise Prescribing Info
Enalapril maleate
All grades of essential HTN. Renovascular HTN. All degrees of heart failure. Prevention of symptomatic heart failure. Prevention of coronary ischemic events in patients w/ left ventricular dysfunction.
Dosage/Direction for Use
Essential Mild HTN Initially 10 mg daily. Other degrees of HTN Initially 20 mg daily. Maintenance: 20 mg once daily. Max: 40 mg daily. Renovascular HTN Initiate w/ lower starting dose (eg, ≤5 mg) & adjust accordingly to patient's needs. Mild renal impairment (CrCl >30 to <80 mL/min) Initially 5-10 mg daily. Moderate renal impairment (CrCl >10 to ≤30 mL/min) Initially 2.5-5 mg daily. Severe renal impairment (CrCl ≤10 mL/min) Initially 2.5 mg daily on dialysis days, adjusted depending on BP response on nondialysis days. Heart failure/asymptomatic left ventricular dysfunction Initially 2.5 mg administered under close medical supervision to determine initial effect on BP, may be increased gradually to 20 mg in single or 2 divided doses as maintenance over 2-4 wk period.
May be taken with or without food.
Hypersensitivity. History of angioneurotic edema related to previous treatment w/ ACE inhibitor. Hereditary or idiopathic angioedema. Concomitant use w/ aliskiren in patients w/ diabetes. Combination w/ neprilysin inhibitor eg, sacubitril.
Special Precautions
Hypersensitivity. Anaphylactoid reactions during hymenoptera desensitization. Angioneurotic edema. Symptomatic hypotension in vol-depleted patients eg, by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting; patients w/ ischemic heart or cerebrovascular disease, severe heart failure; obstruction in left ventricle outflow. Cough; DM. Hypoglycemia. Major surgery or during anesth. Concomitant use w/ K-sparing diuretics, K supplements, K-containing salt substitutes or drugs that increased serum K. Hemodialysis patients; renal insufficiency; acute renal failure; bilateral renal or solitary kidney artery stenosis. Not recommended during pregnancy. Lactation. Not to be used in childn.
Adverse Reactions
Dizziness, headache. Fatigue, asthenia; hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash, cough.
Drug Interactions
Additive effect w/ other antihypertensive therapy. Development of hyperkalemia w/ K-sparing diuretics, K supplements, K-containing salt substitutes or drugs that increased serum K. Increased blood glucose-lowering effect w/ antidiabetic drugs. Reduced lithium clearance. Attenuated antihypertensive effect by NSAIDs including selective COX-2 inhibitors. Increased risk of hypotension, syncope, hyperkalemia, renal function changes w/ aliskiren & angioedema w/ mammalian target of rapamycin & neprilysin inhibitors. Nitritoid reactions w/ injectable gold.
ATC Classification
C09AA02 - enalapril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
Renitec tab 10 mg
Renitec tab 5 mg
Renitec tab 20 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in